Continuous treatment with Kesimpta sees RMS patients achieving NEDA-3

Study highlights benefit of initiating high-efficacy therapies early for relapsing multiple sclerosis (RMS) patients, as opposed to changing from lower efficacy therapies later.

Related Keywords

Vienna ,Wien ,Austria ,Ludwig Kappos ,European Academy Of Neurology ,University Hospital Basel ,Novartis ,Professor Ludwig Kappos ,University Hospital ,Cognitive Processing Speed ,Relapsing Multiple ,European Academy ,